Shares of United Therapeutics stock shot up 33% on Sept. 2 to an all-time high after the company announced positive results for its drug, Tyvaso, in patients with a chronic lung disease called idiopathic pulmonary fibrosis.
On Wednesday United Therapeutics stock got a nine-point Relative Strength (RS) Rating upgrade, from 78 to 87. The upgraded 87 RS Rating shows that the Silver Spring, Md.-based medical company's stock is in the top 13% of all stocks for price appreciation over the last 52 weeks.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating of above 80 as they launch their biggest runs.
Among its other key ratings United Therapeutics carries an 84 EPS Rating out of 99. It also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. The best growth stocks have a Composite Rating of 90 or better.
Additionally, it has a best-possible SMR Rating (sales +profit margins + return on equity) of A. And its B- Accumulation/Distribution Rating shows that institutional investors like ETFs and university funds are buying more of its shares than selling.
Looking For The Best Stocks To Buy And Watch? Start Here
United Therapeutics develops treatments for heart diseases and cancer.
Last quarter the company reported a 10% rise in earnings to a hefty $6.41 per share on 12% higher revenue, to $798.6 million. The prior three stanzas it recorded EPS gains of 19%, 425 and 7% on sales increases of 23%, 20% and 17%.
UTHR stock broke out earlier, but is now about 5% below the prior 417.81 entry from a consolidation. After its 33% surge to a record 436.95 on Sept. 2, it consolidated, dropping to a 375.61 low on Sept. 5. It's been rising again lately and traded at XX Wednesday afternoon, XX for the day.
United Therapeutics holds the No. 11 rank among its peers in the 688-stock Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Argenx are among the top 5 highly rated stocks within the group.
IBD's proprietary Relative Strength Rating measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
Please follow James DeTar on Twitter @JimDeTar
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
